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Abstract 
Background: Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are 
frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome 
remain uncertain. 
Patients and methods: Women with stage I–II breast cancer treated with adjuvant adriamycin and cyclophosphamide (AC) from 1990–
95 were identified in a provincial breast cancer database. Cases were classified into four cohorts: (1) all cycles delivered at full dose and 
on time; (2) one single dose reduction or dose delay; (3) >1 dose reduction or dose delay; (4) <2 cycles of chemotherapy delivered. 
Results: 484 eligible cases were identified (cohort (1): n = 268; (2): n= 88; (3): n= 89; (4) n= 39). Slight imbalances in lymph node status 
(p=0.05) and adjuvant hormonal therapy (p=0.05) were observed between the cohorts. Fifty-five per cent (267/484) of the patients had 
node-positive disease and 33% (158/484) were ER+. 45% of cases had a reduction in DI. With a median follow-up of 9.6 years, there 
were no significant differences in relapse-free survival (p=0.94), breast cancer-specific survival (p=0.87) or overall survival (p=0.86) 
between the four cohorts. Outcomes were independent of hormone receptor status. 
Conclusions: Although toxicity related reductions in the DI of adjuvant AC chemotherapy for early stage breast cancer are common, 
they did not appear to significantly impact on clinical outcomes in this population-based cohort of women with stage I–II breast cancers. 
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Introduction 
The benefits of adjuvant chemotherapy on clinical outcomes in 
early stage breast cancer have been well established [1, 2]. In 
the latest Early Breast Cancer Trialists’ Collaborative Group 
overview of the randomized trials in early breast cancer, 
anthracyclines were shown to be superior to non-anthracyclines 
in reducing recurrences and breast cancer deaths [1]. The 
concept of dose intensity (DI), defined as the amount of drug 
delivered per unit time (mg/m
2/week), and its impact on breast 
cancer outcomes has been an area of intensive research. The 
French Adjuvant Study Group (FASC) 05 trial compared high 
and low (50%) DI of epirubicin in a combination containing 
fluorouracil, epirubicin and cyclophosphamide [3]. The higher DI 
arm yielded significant improvements in disease free survival 
(DFS) and overall survival (OS). Similarly, the Cancer and 
Leukaemia Group B (CALGB) 8541 trial compared high, 
intermediate and low DI of doxorubicin, using the combination of 
cyclophosphamide, doxorubicin and fluorouracil [4]. Women 
treated at the high and intermediate DI had significantly 
improved DFS and OS over the low DI group. An ensuing 
CALGB study (9344) found that anthracycline DI exceeding the 
highest used in the CALGB 8541 study (60 mg/m
2 every 21 
days) failed to further improve survival but was associated with 
increased treatment-related toxicity [5]. Furthermore, a dose 
effect of escalating cyclophosphamide has not been identified 
as beneficial in two randomized trials [6, 7]. Taken together 
these trials demonstrate that within the standard anthracycline 
dose range a threshold effect exists, meaning it is less 
efficacious to deliver adjuvant chemotherapy, using sub-optimal 
dose intensity and/or lower cumulative doses of anthracyclines. 
In order to maximally improve survival for women with early 
stage breast cancer, a critical (or threshold) dose intensity 
and/or cumulative anthracycline dose must be reached. 
It remains controversial at what threshold a reduction in DI, 
other than ≤50%, adversely impacts on clinical outcomes. A 
retrospective analysis of the pivotal Milan trial using classical 
cyclophosphamide methotrexate fluorouracil (CMF) suggests 
that the women who received less than 85% of their scheduled 
dose had worse clinical outcomes [8, 9]. In addition, women 
who received less than 65% of their scheduled dose did no 
better than those treated with surgery alone. However, more 
recent retrospective data from larger cohorts of women treated 
with classical or intravenous CMF have failed to demonstrate a 
statistically significant correlation between DI of chemotherapy 
and clinical outcomes [10, 11]. 
Reduced dose intensity of adjuvant chemotherapy because of 
toxicity or poor treatment tolerance in primary breast cancer is a 
common occurrence [12]. In a US-wide study of community 
practices with close to 20,000 women with early stage breast 
cancer treated with adjuvant chemotherapy, 55.5% of patients 
received a DI of less than 85%. Doxorubicin and cyclophosphamide 
(AC) is a commonly used combination for the treatment of early 
stage breast cancer. We have examined the impact of a reduced DI 
of four cycles of AC on clinical outcomes of patients with early stage 
breast cancer treated at the British Columbia Cancer Agency 
(BCCA) between 1990 and 1995.  
 
Methods 
The province of British Columbia (BC) has a population of 
approximately four million people. In 2005, close to 2600 new 
cases of breast cancer were diagnosed, and 620 breast cancer 
related deaths were recorded. Approximately 75% of all cases 
of breast cancer diagnosed in the province are referred to a 
BCCA centre. The BCCA has the mandate for cancer control for 
the entire province. This includes the operation of four regional 
cancer centres delivering all the radiation therapy in the 
province, and the management of the provincial budget for all 
cancer systemic therapies. The BCCA is also responsible for 
the establishment of provincial, evidence-based guidelines 
regarding access to systemic agents in the treatment of all solid 
and haematological malignancies. A central pharmacy database 
within the BCCA records the date, drug and dose of all systemic 
agents and their indication in the treatment of a specific cancer 
in every patient. The BCCA also manages a Breast Cancer 
Outcomes Database (BCOD). The BCOD contains detailed 
demographic, pathologic, staging, treatment and outcome data 
for women diagnosed with breast cancer since 1 January 1989 
and referred to the BCCA. Information on the date and site of 
first local, regional and distant relapse is collected prospectively. 
Date and cause of death is collected from the provincial death 
registry. 
The BCCA pharmacy database and the BCOD were used to 
identify women with stage I–II breast cancer who were treated 
with standard adjuvant AC chemotherapy (A: 60 mg/m
2; C: 
600mg/m
2; administered every 21 days for a total of four cycles) 
between 1990 and 1995. During this time period G-CSF was not 
routinely used for patients receiving adjuvant chemotherapy at 
the BCCA. Women with bilateral invasive breast cancers 
diagnosed within ten years of each other and more than one  
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month apart were excluded from the study. The reasons for 
dose adjustments were not determined for this study, but are 
assumed to be related to treatment toxicity, patient preference 
and/or physician preference. The treatment data were then 
linked to the BCOD to determine clinical outcomes. 
Standard BCCA guidelines for the management of treatment-
related side effects state that with the AC regimen, both 
adriamycin and cyclophosphamide should each be reduced by 
25% for mild myelosuppresion on day 1 of any treatment cycle 
(defined as: absolute neutrophil count (ANC) 1.0–1.49 × 10
9/l 
and/or platelets 70–89 × 10
9/l) or that treatment be delayed for 
more severe myelosuppresion on day 1 of any treatment cycle 
(defined as ANC < 1.0 × 10
9/l and/or platelets <70 × 10
9/l). 
Reductions in AC dose are recommended for either 
hyperbilirubinemia (adriamycin is reduced 50% if serum bilirubin 
is 20–51 µmol/l, 75% if the serum bilirubin is 51–85 µmol/l and 
discontinued if the serum bilirubin is >85 µmol/l) or severe renal 
dysfunction (cyclophosphamide is reduced by 25% if the 
creatinine clearance is <10 ml/min). 
Reduced DI was defined as: (1) a 25% reduction from the 
starting dose of at least one of the chemotherapeutic agents 
(per cycle), or (2) a dose delay of at least five days (per cycle). 
The patients were then grouped into one of four cohorts: (1) 
entire treatment course delivered at full doses and on schedule; 
(2) one single dose reduction or one single dose delay during 
the entire treatment course; (3) >1 dose reduction or dose delay 
during the entire treatment course; and (4) ≤2 cycles of 
treatment delivered. The rationale in segregating dose intensity 
of AC into these four cohorts was based on our primary interest 
in assessing the outcome between cohorts 1 and 2. It appears 
clinicians often initiate growth factor support upon the first 
occurrence of either a dose reduction or delay of adjuvant 
chemotherapy without much clinical evidence to support this 
practice. The BCOD, provincial pharmacy database and uniform 
treatment guidelines allowed us to attempt to address this 
dilemma in a retrospective manner. 
Relapse free survival (RFS) was defined as the time from initial 
pathologic diagnosis of the primary breast cancer until the first 
relapse (local, regional or distant) or death from breast cancer in 
the absence of a documented relapse. Overall survival (OS) 
was defined as the time from initial pathologic diagnosis of the 
primary breast cancer until death from any cause. Breast cancer 
specific survival (BCSS) was defined as the time from initial 
pathologic diagnosis of the primary breast cancer until death 
related to breast cancer. Where cause of death was unknown, it 
was attributed to breast cancer if there was a documented 
regional or distant relapse, or subsequent new primary 
contralateral breast cancer. 
The  χ
2 statistic was used to compare categorical variables. 
Continuous variables were compared using analysis of 
variance. RFS, BCSS and OS rates were computed using the 
Kaplan-Meier method. Statistical comparisons of Kaplan-Meier 
curves were conducted using the log-rank test. Ethics approval 
was granted for this study from the BCCA research and ethics 
board. 
No external funding was required for this study. 
Results
Patient characteristics
Four-hundred-and-eighty-four cases were identified. Two-
hundred-and-sixty-eight patients (55.4%) received their full 
course of treatment on time and at 100% DI (cohort 1). Eighty-
eight patients (18.2%) had one dose reduction or dose delay 
(cohort 2) and 89 patients (18.4%) had more than one dose 
delay or dose reduction throughout treatment of at least three 
cycles of chemotherapy (cohort 3). Only 39 patients (8.1%) 
received two or fewer cycles of therapy (cohort 4). 
The cohorts were well matched for characteristics of prognostic 
significance such as age, menopausal status, size of the 
primary lesion, tumour grade, oestrogen receptor status and 
surgical margins (Table 1). Nodal status (p=0.05) and use of 
adjuvant hormonal therapy (p=0.05) differed significantly 
between the cohorts. Sixty-six per cent of patients in cohort 2 
had axillary node involvement, while only 56.2%, 47.7% and 
46.2% had axillary node involvement in cohorts 1, 3 and 4, 
respectively. In cohort 2, 62.5% of women were prescribed 
adjuvant hormonal (e.g. tamoxifen) therapy, while only 48.9%, 
42.7% and 46.2% women in cohorts 1, 3 and 4, respectively, 
were prescribed adjuvant hormonal therapy. The level of Her-
2/neu expression was not tested in patients diagnosed with 
primary breast cancer in the period of this study. 
Survival
The median follow-up duration of the total cohort of patients was 
9.6 years. During adjuvant treatment, 45% of patients required 
at least one dose reduction or dose delay. The clinical end 
points of RFS, BCCS and OS were not significantly different 
among the four cohorts (Table 2). The eight-year survival 
estimates for cohorts 1–4, respectively, were: RFS 72%, 74%, 
74%, 68%; BCSS 80%, 77%, 82%, 80%; and OS 78%, 76%, 
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Table 1: Patient characteristics at the time of diagnosis. 
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Table 2: Eight-year survival data. 
 
80%, 77% (Figure 1a and b). Survival was further analysed 
based on endocrine responsiveness. For the 158 (33%) ER(−) 
breast cancer cases included in the study, the eight-year RFS, 
BCSS and OS were also not significantly different among the 
four cohorts (Table 2, Figure 1c and d). Likewise, the eight-year 
figures were not significantly different among the four cohorts 
for the 267 (55%) ER(+) breast cancer cases (Table 2, Figure 
1e and f). Overall, 65.3% of the patients with ER(+) breast 
cancer were treated with adjuvant tamoxifen (Table 3). The 
differential prescription of tamoxifen across the cohorts, in 
particular cohort 2 versus cohort 1, was due to the provincial 
guidelines, which in that period, did not recommend adjuvant 
tamoxifen in pre-menopausal patients with node negative breast 
cancer (higher rate of node negative breast cancer in cohort 1 
versus cohort 2 because the clinical benefit of adjuvant 
tamoxifen in pre-menopausal breast cancer had not yet been 
ascertained. 
 
Discussion
Modern adjuvant breast cancer treatment is increasingly 
dependent on biological features to guide prognosis and 
therapy. While the classic clinical prognostic factors such as 
lymph node status, grade and stage remain important, 
prognostic and predictive factors such as endocrine 
responsiveness (ER and PR status), as well as the HER-2/neu 
status of tumours are now routinely used to further refine 
therapy. Hormonal therapies, such as tamoxifen, aromatase 
inhibitors and ovarian ablation, and monoclonal antibody 
therapy using trastuzumab are therapeutic options, which have 
been shown to improve patient outcomes and are commonly 
used adjuncts to chemotherapy in properly selected patients 
[13]. While there is a breadth of chemotherapy options (e.g. 
anthracycline-based, anthracycline and taxane-based, dose 
dense) the AC regimen remains a commonly used form of 
chemotherapy. It may be considered as the sole treatment 
modality in low-risk, endocrine non-responsive disease, or more 
often, it will form part of a treatment plan such as AC for four 
cycles followed by a taxane, with or without subsequent 
hormone therapy or trastuzumab. Therefore, it is important to 
understand the possible impact of dose modifications of AC 
therapy on clinical outcomes. 
Randomized controlled trials have shown that not only the 
cumulative dose of chemotherapeutic agents, but also the
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(a) 
 
(b) 
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(c) 
 
(d) 
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(e) 
 
(f) 
 
Figure 1: (a) relapse-free survival for all cases, (b) overall survival for all cases, (c) relapse-free survival for ER(−) cases, (d) overall survival for 
ER(−) cases, (e) relapse-free survival for ER(+) cases, (f) overall survival for ER(+) cases.
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Table 3: Proportion of patients with ER(+) breast cancer who received tamoxifen (N=265). 
delivery schedule may be important for improving breast cancer 
outcomes [14, 15]. Early results of the CALGB 9741 trial 
suggest that increasing the dose density of AC for four cycles 
followed by paclitaxel for four cycles (AC+T) through the use of 
haematopoietic growth factors to deliver the regimen every two 
weeks, compared to the identical regimen every three weeks, 
improves RFS and OS in women with node positive breast 
cancer [15]. The absolute benefit on RFS and OS at three years 
was 4% and 2%, respectively, for the dose dense regimen, 
indicating a small, though significant improvement. Women with 
lower risk, node negative early breast cancer were not included 
in this study. Although they may potentially benefit from the 
addition of a taxane to the dose dense adjuvant anthracycline 
regimen (AC+T), the absolute gain is expected to be even 
smaller in this patient population [5, 15, 16]. For these lower-risk 
women, a regimen such as standard dose AC for four cycles is 
still quite appropriate. In fact, a recent trial (E2137) compared 
concurrent doxorubicin and docetaxel for four cycles to AC for 
four cycles in 2889 women with early breast cancer (of which 
65% were node negative), and demonstrated no difference in 
DFS or OS between the two regimens [17].  
Although generally well tolerated, AC can still lead to toxicity 
and dose reductions or delays. A survey of community 
oncologists across the United States has reported that of 6849 
women with primary breast cancer treated with AC, 29% 
experienced a dose reduction of ≥15% or a delay of ≥7 days at 
some time during their course of treatment [12]. That study did 
not assess the impact of this on patient outcomes. In our study 
of patients treated with four cycles of adjuvant AC, dose 
modifications (of ≥25% in any cycle) or delays (of ≥5 days in any 
cycle) were experienced by 45% of patients. 
Recognizing a threshold effect of both cumulative dose and 
dose intensity of anthracyclines, and in light of emerging 
evidence that dosing schedules may impact on outcome in 
women with node positive breast cancer, oncologists are 
concerned that any single-dose modifications or delays, even 
for the management of asymptomatic neutropenia, will 
compromise clinical benefit. Oncologists are known to utilize 
haematopoietic growth factors if dose reductions or delays in 
adjuvant anthracycline-based chemotherapy have been 
required [12]. Recent data also suggest that chemotherapy 
dose intensity may be particularly important for patients with 
ER(−) disease [18]. However, our retrospective population-
based analysis of women with early stage breast cancer treated 
with up to four courses of standard adjuvant AC has not 
identified a relationship between DI and clinical outcome despite 
nearly a decade of follow-up. When endocrine responsiveness 
was considered no difference in outcome was appreciated 
between the four cohorts. 
The definitions of dose reductions and delays in this study 
reflect the actual modifications commonly used by medical 
oncologists at the BCCA in managing treatment related toxicity 
(haematological and non-haematological). The four cohorts 
were designed to identify a relationship between incremental 
dose adjustments (and hence, intensity) and outcome. We 
specifically included a cohort of patients with only one dose 
adjustment during their treatment course, in order to assess the 
impact of a single-dose modification on clinical outcome. The 
lack of difference in outcome between patients in cohorts 1 (full 
dose without delays) and 2 (one dose adjustment) suggests that 
when a single reduction in dose intensity (whether through dose 
delay of ≥5 days or dose reduction of 25%) is required, it is 
reasonable to refrain from adding haematopoietic growth factors 
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for subsequent cycles, if the only intention is to maintain dose 
intensity. This is further supported by the fact that there is again 
no statistical difference in outcome between cohorts 1 and 3 (>1 
dose reduction or >1 dose delay, and at least three cycles of 
chemotherapy), suggesting that those patients who go on to 
have a second dose adjustment for ongoing toxicity still have 
similar outcomes. These results reflect reduced DI for only four 
cycles of standard dose AC, and may not necessarily hold true 
for newer generation 6–8 cycle chemotherapy regimens (such 
as TAC, CEF, CVAP-D, AC-Docetaxel) currently being utilized 
as adjuvant or neoadjuvant therapy in high-risk breast cancer 
[16, 19–22]. 
Our results may be explained by the small difference in relative 
DI (RDI) between the cohorts (cohort 1, RDI = 100%; cohort 2, 
RDI = 93.7–95.7%; cohort 3 (e.g. if two cycles of chemotherapy 
are delivered with a 25% dose reduction), RDI = 88.9%). 
Although the size of our study cohorts may limit the statistical 
power to detect a small difference in outcome, the long duration 
of follow-up, as well as the population-based nature of these 
data suggests that one single-dose reduction or dose delay 
during a planned four-cycle regimen of adjuvant AC 
chemotherapy can be undertaken with minimal detriment to the 
long-term outcomes and without need for haematopoietic 
support. 
While cohort 4 appears to have received the lowest RDI, the 
true treatment delivered to these patients is not known. Some 
patients may have received treatment at other cancer treatment 
centres, or switched to alternative regimens. The small number 
of patients in cohort 4 (n=39) prohibits definitive conclusions 
from being drawn. However, the FASG 05 and CALBG 8541 
trials clearly demonstrated a DI of ≤50% of the anthracycline 
lessens the benefit of adjuvant chemotherapy. 
There is an important conceptual difference between the 
intentional, a priori reduction of the delivered dose (such as the 
study design of the FASC 05 and the CALGB 8541 trials [2, 3], 
and dose reduction specifically for treatment-related toxicity. 
Prospective trials that demonstrate a threshold effect of an 
anthracycline prove that on a population basis, a certain 
cumulative dose and/or dose intensity is required to improve 
outcomes. For doxorubicin, the threshold is generally believed 
to be around 60 mg/m
2 when the drug is delivered on a three-
weekly schedule, however, whether the true threshold dose lies 
somewhere just below 60 mg/m
2 is not known. Importantly, the 
effective  threshold doses for individuals within a population 
are not known. Presumably, some patients may have a 
threshold at a dose less than 60 mg/m
2. It has been suggested 
that haematological toxicity may serve as a marker to identify 
the appropriate threshold DI for an individual patient [23]. This 
has not been evaluated in a prospective fashion; however, 
retrospective data examining the impact of treatment-related 
leucopoenia and outcome suggest that patients who experience 
haematological toxicity may in fact have better clinical outcomes 
[10, 11, 24]. Conversely, those who do not experience adequate 
haematological toxicity may be receiving less than their optimal 
individual threshold dose of chemotherapy. If this model is 
applied to the context of treatment-related toxicity, it would 
suggest that patients experiencing toxicity were initially 
receiving a dose at or in excess of their individual threshold. If 
the model is assumed to be accurate, dose reductions and 
delays for toxicity can be applied and are unlikely to impact on 
outcome. 
An association between hormone responsiveness and DI has 
recently been reported [18, 25]. Patients with ER(−) breast 
cancer who receive <85% of their protocol specified dose of 
CMF chemotherapy for cycle 1 of treatment had worse DFS and 
OS compared to those patients who received >85% of their 
protocol-specified dose for cycle 1. While our study did not 
show a difference in outcome based on ER status, conceptually 
the question addressed in the study by Colleoni et al [18] and 
our study is different. In our study, dose intensity was reduced 
only for treatment-related toxicity, while the Colleoni et al 
analysis considered patients whose doses were reduced a 
priori, for cycle 1 of treatment. The possibility that many of 
these patients could have tolerated higher doses and were in 
fact being treated below their individual chemotherapy threshold 
cannot be ruled out. 
Several studies are frequently cited to illustrate the relationship 
between DI and clinical outcome. In these studies, patients who 
received <85% of their scheduled chemotherapy dose had 
worse clinical outcomes [8, 24]. It is important to note that these 
results are based on retrospective analyses of clinical trials 
conducted in the late 1970s and 1980s, using a non-
anthracycline-based regimen of CMF. The dose adjustments for 
toxicity, especially haematological toxicity, applied to these 
studies can be considered conservative by today’s standards. 
For example, in the retrospective analysis of Bonadonna et al 
[8], chemotherapy doses were reduced by 50% in the presence 
of Grade 1 myelosuppression. Fifty per cent dose reductions 
are rarely used in modern day chemotherapy. By reducing the 
dose so markedly at the first occurrence of Grade 1 toxicity, the 
researchers may have reduced the dose intensity below the 
individual’s threshold. That is, if smaller increments could have 
been used, it is possible that more patients would have received 
a greater proportion of their scheduled dose, and the results of 
the analysis may have been substantially different. 
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Prospective randomized trials to define the impact of toxicity-
related reductions in DI on clinical outcomes are unlikely to be 
conducted. Although reduced dose intensity of AC 
chemotherapy for early stage breast cancer is common, the 
results of this population-based study indicate that a single-dose 
reduction or delay of AC chemotherapy for women with early  
 
stage breast cancer may not impact on clinical outcomes, and 
require no additional interventions, particularly in lower risk 
patients such as stage I breast cancer. Furthermore, 
retrospective studies from either clinical trials or large 
population-based databases may help to further confirm or 
refute this hypothesis. 
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